ClinicalTrials.gg
CompletedNCT06961708Updated Apr 6, 2026Results posted

A Study of Fosmanogepix in Healthy Adult Chinese Subjects

A Phase 1 interventional study of Oral Fosmanogepix and IV Fosmanogepix in Healthy, sponsored by Basilea Pharmaceutica. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study was to investigate the pharmacokinetics and safety of the investigational drug fosmanogepix including its active moiety manogepix following a single dose and multiple doses (by intravenous infusion (IV) or orally) in healthy Chinese adults.

The study consisted of 2 consecutive Parts (Part-1, single-dose part followed by Part-2, multiple-dose part) including a total of 54 subjects (32 subjects in Part-1 and 22 subjects in PART-2) randomized.

Read the detailed description

Part-1 duration including screening period was up to 64 days including 4 visits at the clinical site and Part-2 duration including screening period was up to 70 days including 5 visits at the clinical site. The study included a total of 4 study sub-groups (Cohorts 1-4) in which fosmanogepix or placebo was administered in different strengths orally or IV.

Subjects were enrolled and randomly assigned to study drug.

During the study, serial blood samples were collected to understand how fosmanogepix was changed and eliminated from the body.

The primary objective of PART-1 (Single-dose) was to evaluate the pharmacokinetic (PK) profile of manogepix (active moiety of fosmanogepix) after single dose administration in healthy adult Chinese subjects.

The primary objective of PART-2 (Multiple-dose) was to evaluate the PK profile of manogepix (active moiety of fosmanogepix) after repeated doses in healthy adult Chinese subjects.

All data analyses are descriptive (no statistical analysis is provided).

02

Conditions studied

  • Healthy

Keywords

  • Fosmanogepix
  • Manogepix
  • Chinese
  • Pharmacokinetics
  • Healthy adults
03

In context

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main criteria for inclusion and exclusion:

  • (BMI) of 18.0 to 30.0 kg/m2 inclusive, and a total body weight > 45 kg for females and > 50 kg for males at Screening.
  • Subjects who were overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, vital signs, creatinine, and estimated (Cockcroft-Gault formula).

Main exclusion criteria:

  • Active acute or chronic infection, including, but not limited to upper airway infection, urinary tract infection, or skin infection at Screening.
  • Any condition possibly affecting drug absorption.
  • Medical history of neurological disorders including abnormal movements or seizures.
  • Use of prescription or non-prescription drugs, including vaccines, and dietary and herbal supplements from Screening or within five half-lives (whichever is longer) prior to the first dose of study drug and throughout the study.
  • Screening supine blood pressure (BP) ≥ 140 mmHg (systolic) or ≥ 90 mmHg (diastolic), and pulse rate (PR) > 100 beats per minute (bpm) or \< 50 bpm, following at least 5 minutes of supine rest.
  • Body temperature higher than 37.5 °C.
  • Screening supine 12 lead demonstrating abnormalities that may affect subject safety or interpretation of study results.
  • Subjects with any of the following abnormalities in clinical laboratory tests at Screening, as assessed by the local laboratory and confirmed by a single repeat test, if deemed necessary:
  • or ALT ≥ 1.0 × .
  • Total ≥ 1.5 × ULN.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Single-dose Part -1 (Cohort 1, oral)

    Subjects received fosmanogepix or placebo by oral administration

    Drug: Oral Fosmanogepix · Drug: oral placebo

  • Experimental
    Single-dose Part-1 (Cohort 2, IV)

    Subjects received fosmanogepix or placebo by IV infusion

    Drug: IV Fosmanogepix · Drug: IV placebo

  • Experimental
    Multiple-dose Part-2 (Cohort 3, IV)

    Subjects received fosmanogepix or placebo as an IV infusion twice 12 hours apart on Day 1 followed by a maintenance daily dose of fosmanogepix or placebo via IV infusion from Day 2 to Day 7

    Drug: IV Fosmanogepix · Drug: IV placebo

  • Experimental
    Multiple-dose Part-2 (Cohort 4, IV followed by oral)

    The subjects received fosmanogepix or placebo as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7.

    Drug: Oral Fosmanogepix · Drug: IV Fosmanogepix · Drug: IV placebo · Drug: oral placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-1

    Pharmacokinetic (PK) parameter Cmax for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

    Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose

  2. Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-1

    PK parameter Tmax for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

    Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose

  3. Area Under the Plasma Concentration vs. Time Curve for 0-24 Hours (AUC24) of Manogepix in Part-1

    PK parameter AUC 24 for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

    Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose

  4. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Manogepix in Part-1

    PK parameter AUClast for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

    Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose

  5. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Manogepix in Part-1

    PK parameter AUC (0 - ∞) for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

    Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose

  6. Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-2

    PK parameter Cmax after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose from Day 2 to Day 7 or followed by an IV maintenance dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7

    Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240, 360 hours postdose on Day 7

  7. Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-2

    PK parameter Tmax after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7

    Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240, 360 hours postdose on Day 7

  8. Area Under the Concentration-time Curve at Steady State Over the Dosing Interval Tau (AUCtau) of Manogepix in Part-2

    PK parameter AUCtau after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose from Day 2 to Day 7 or followed by an IV maintenance dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7

    Time frame: pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240, 360 hours postdose on Day 7

Secondary outcomes

  1. Fraction of Unbound Manogepix in Plasma in Part 1

    The fraction of unbound manogepix has been assessed after single dose administration (oral / IV)

    Time frame: pre-dose and 3 hours postdose

  2. Number of Subjects With Treatment-emergent AE (TEAE) in Part-1

    A TEAE was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug

    Time frame: Up to 36 days

  3. Number of Subjects With TEAE in Part-2

    A TEAE was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug

    Time frame: Up to 42 days

07

Results

Posted Mar 11, 2026

Participant flow

The study was conducted at one site in China

Participant flow — Overall Study
MilestoneSingle-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)Single-dose Part-1 (Placebo)Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)Multiple-dose Part-2 (Placebo)
Started66668994
Completed66668784
Not completed00000210
Withdrew: Adverse event00000100
Withdrew: Did not receive study drug due to safety finding pre-dose00000110

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Manogepix in Part-1

Pharmacokinetic (PK) parameter Cmax for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

Time frame:
pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-1
ng/mLSingle-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)
Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-15750 ± 39.510865 ± 12.98343 ± 31.113874 ± 18.0
PrimaryTime to Peak Manogepix Concentration (Tmax) of Manogepix in Part-1

PK parameter Tmax for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

Time frame:
pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose
Reported as:
Median · hour
Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-1
hourSingle-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)
Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-12.50 (2.00 to 3.00)3.00 (2.00 to 4.00)2.96 (2.85 to 3.05)2.99 (2.87 to 3.05)
PrimaryArea Under the Plasma Concentration vs. Time Curve for 0-24 Hours (AUC24) of Manogepix in Part-1

PK parameter AUC 24 for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

Time frame:
pre-dose, 1, 2, 3, 4, 6, 8, 12, 24 hours postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration vs. Time Curve for 0-24 Hours (AUC24) of Manogepix in Part-1
h*ng/mLSingle-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)
Area Under the Plasma Concentration vs. Time Curve for 0-24 Hours (AUC24) of Manogepix in Part-149823 ± 17.389822 ± 25.376270 ± 32.3132743 ± 28.2
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Manogepix in Part-1

PK parameter AUClast for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

Time frame:
pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Manogepix in Part-1
h*ng/mLSingle-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Manogepix in Part-1148314 ± 12.1278079 ± 16.8257783 ± 30.5407819 ± 12.6
PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Manogepix in Part-1

PK parameter AUC (0 - ∞) for manogepix after a single oral administration of 400 mg or 800 mg fosmanogepix or after a single IV infusion of 600 mg or 1,000 mg fosmanogepix over 3 hours to healthy Chinese subjects

Time frame:
pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240 hours postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Manogepix in Part-1
h*ng/mLSingle-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of Manogepix in Part-1156539 ± 14.4296639 ± 17.7266920 ± 33.4440974 ± 9.7
PrimaryMaximum Observed Plasma Concentration (Cmax) of Manogepix in Part-2

PK parameter Cmax after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose from Day 2 to Day 7 or followed by an IV maintenance dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7

Time frame:
pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240, 360 hours postdose on Day 7
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-2
ng/mLMultiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)
Maximum Observed Plasma Concentration (Cmax) of Manogepix in Part-214665 ± 17.116459 ± 7.6
PrimaryTime to Peak Manogepix Concentration (Tmax) of Manogepix in Part-2

PK parameter Tmax after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7

Time frame:
pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240, 360 hours postdose on Day 7
Reported as:
Median · hour
Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-2
hourMultiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)
Time to Peak Manogepix Concentration (Tmax) of Manogepix in Part-22.90 (2.87 to 2.97)3.50 (2.00 to 6.00)
PrimaryArea Under the Concentration-time Curve at Steady State Over the Dosing Interval Tau (AUCtau) of Manogepix in Part-2

PK parameter AUCtau after fosmanogepix administration as an IV infusion twice 12 hours apart on Day 1 followed by an IV maintenance daily dose from Day 2 to Day 7 or followed by an IV maintenance dose on Day 2 and Day 3, and then switched to oral administration (of fosmanogepix or placebo) daily from Day 4 to Day 7

Time frame:
pre-dose, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 144, 240, 360 hours postdose on Day 7
Reported as:
Geometric mean · h*ng/mL
Area Under the Concentration-time Curve at Steady State Over the Dosing Interval Tau (AUCtau) of Manogepix in Part-2
h*ng/mLMultiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)
Area Under the Concentration-time Curve at Steady State Over the Dosing Interval Tau (AUCtau) of Manogepix in Part-2224722 ± 24.2258780 ± 8.4
SecondaryFraction of Unbound Manogepix in Plasma in Part 1

The fraction of unbound manogepix has been assessed after single dose administration (oral / IV)

Time frame:
pre-dose and 3 hours postdose
Reported as:
Geometric mean · percentage
Fraction of Unbound Manogepix in Plasma in Part 1
percentageSingle-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)
Fraction of Unbound Manogepix in Plasma in Part 10.109 ± 11.40.105 ± 22.30.192 ± 27.10.226 ± 8.2
SecondaryNumber of Subjects With Treatment-emergent AE (TEAE) in Part-1

A TEAE was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug

Time frame:
Up to 36 days
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-emergent AE (TEAE) in Part-1
ParticipantsSingle-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)Single-dose Part-1 (Placebo)
Any study drug-related TEAE53010
Any treatment-emergent serious adverse event (SAE)00000
Any study drug-related TEAE leading to treatment discontinuation00000
None TEAE13658
SecondaryNumber of Subjects With TEAE in Part-2

A TEAE was defined as any event not present prior to the first administration of the study drug, or any event already present that worsens in either severity or frequency following exposure to the study drug

Time frame:
Up to 42 days
Reported as:
Count of participants · Participants
Number of Subjects With TEAE in Part-2
ParticipantsMultiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)Multiple-dose Part-2 (Placebo)
Any study drug-related TEAE not leading to treatment discontinuation472
Any study drug-related TEAE leading to treatment discontinuation100
Any treatment-emergent SAE000
None TEAE312

Adverse events

Collected over Overall up to 42 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single-dose Part -1 (Cohort 1, Oral 400 mg)0/6 (0%)0/6 (0%)5/6 (83.3%)
Single-dose Part -1 (Cohort 1, Oral 800 mg)0/6 (0%)0/6 (0%)3/6 (50%)
Single-dose Part-1 (Cohort 2, IV 600 mg)0/6 (0%)0/6 (0%)0/6 (0%)
Single-dose Part-1 (Cohort 2, IV 1000 mg)0/6 (0%)0/6 (0%)1/6 (16.7%)
Single-dose Part-1 (Placebo)0/8 (0%)0/8 (0%)0/8 (0%)
Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)0/8 (0%)0/8 (0%)5/8 (62.5%)
Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)0/8 (0%)0/8 (0%)7/8 (87.5%)
Multiple-dose Part-2 (Placebo)0/4 (0%)0/4 (0%)2/4 (50%)
Most frequent other events
Showing 10 of 20
Most frequent other events
EventSingle-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)Single-dose Part-1 (Placebo)Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)Multiple-dose Part-2 (Placebo)
DizzinessNervous system disorders3/61/60/60/60/80/85/80/4
NauseaGastrointestinal disorders2/62/60/60/60/80/85/81/4
LethargyNervous system disorders0/60/60/60/60/83/81/81/4
Haemoglobin decreasedInvestigations0/60/60/60/60/80/80/81/4
HeadacheNervous system disorders0/60/60/60/60/80/82/81/4
Abdominal distensionGastrointestinal disorders0/60/60/60/60/80/82/80/4
Abdominal pain upperGastrointestinal disorders0/60/60/60/60/80/80/81/4
RegurgitationGastrointestinal disorders0/60/60/60/60/80/82/81/4
VomitingGastrointestinal disorders0/60/60/60/60/80/82/81/4
Creatinine renal clearance decreasedInvestigations0/60/60/61/60/80/81/80/4

Baseline characteristics

Demographics and baseline characteristics (Safety set)

Age, Continuous
Age, Continuous(years)Single-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)Single-dose Part-1 (Placebo)Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)Multiple-dose Part-2 (Placebo)Total
Mean33.5 ± 5.7532.3 ± 3.8332.0 ± 7.1338.8 ± 5.0033.4 ± 5.1031.1 ± 5.9133.9 ± 6.3829.5 ± 6.1433.2 ± 5.84
Sex: Female, Male
Sex: Female, Male(Participants)Single-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)Single-dose Part-1 (Placebo)Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)Multiple-dose Part-2 (Placebo)Total
Female221100219
Male4455886343
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Single-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)Single-dose Part-1 (Placebo)Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)Multiple-dose Part-2 (Placebo)Total
Asian6666888452
Height (cm)
Height (cm)(Cm)Single-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)Single-dose Part-1 (Placebo)Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)Multiple-dose Part-2 (Placebo)Total
Mean166.8 ± 8.84160.7 ± 10.67168.2 ± 6.11162.3 ± 4.97171.3 ± 4.37166.9 ± 7.59172.9 ± 7.70168.5 ± 7.00167.5 ± 7.88
Weight (kg)
Weight (kg)(Kg)Single-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)Single-dose Part-1 (Placebo)Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)Multiple-dose Part-2 (Placebo)Total
Mean62.30 ± 8.2662.00 ± 10.7167.97 ± 9.1465.28 ± 6.5171.53 ± 8.8465.13 ± 6.7366.88 ± 8.6960.70 ± 6.7365.70 ± 8.45
BMI (kg/m2)
BMI (kg/m2)(Kg/m2)Single-dose Part -1 (Cohort 1, Oral 400 mg)Single-dose Part -1 (Cohort 1, Oral 800 mg)Single-dose Part-1 (Cohort 2, IV 600 mg)Single-dose Part-1 (Cohort 2, IV 1000 mg)Single-dose Part-1 (Placebo)Multiple-dose Part-2 (Cohort 3, IV 1,000/600 mg)Multiple-dose Part-2 (Cohort 4, IV 1,000/600 mg/Oral 800 mg)Multiple-dose Part-2 (Placebo)Total
Mean22.32 ± 1.6023.87 ± 1.7224.05 ± 3.0524.82 ± 2.9024.34 ± 2.3823.40 ± 2.0022.31 ± 2.0421.35 ± 1.1023.39 ± 2.31
08

Study locations

1 site
  • Shanghai Xuhui Central Hospital, Longchuan North Road
    Shanghai, 200237, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Jul 2025, 3 months.

Results were first posted in Mar 2026, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 8, 2025
StartActual
Apr 14, 2025
Primary completionActual
Jul 15, 2025
CompletionActual
Jul 15, 2025
Results first posted
Mar 11, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06961708
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
May 8, 2025
Start date
Apr 14, 2025
Primary completion
Jul 15, 2025
Completion
Jul 15, 2025
Results posted
Mar 11, 2026
Last update
Apr 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fosmanogepix

Start the discussion